European Radiology

, Volume 28, Issue 5, pp 2107–2114 | Cite as

Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer

  • Hyun Hoon Chung
  • Jae-Weon Kim
  • Noh-Hyun Park
  • Yong Sang Song
  • Gi Jeong Cheon
Nuclear Medicine
  • 86 Downloads

Abstract

Objectives

Using preoperative PET/CT, we evaluated the prognostic value of preoperative [18F]FDG uptake ratio between various metastatic lesions and primary tumour in patients with advanced serous epithelial ovarian cancer (EOC).

Methods

We retrospectively reviewed patients with International Federation of Gynecology and Obstetrics (FIGO) stage III, IV serous EOC who underwent preoperative [18F]FDG PET/CT scans. Clinico-pathological variables and PET/CT parameters such as maximum standardized uptake value of the ovarian cancer (SUVovary), pelvic or para-aortic LN (SUVLN), peritoneal (SUVperit) and distant extra-peritoneal (SUVdist) metastatic lesions, and the metastatic lesion-to-ovarian cancer standardized uptake value ratio were assessed.

Results

Clinico-pathological data were retrospectively reviewed for 97 eligible patients. The median progression-free survival (PFS) was 18 months (range, 6–90 months) and 59 (60.8 %) patients experienced recurrence. In multivariate regression analysis, older age (p = 0.035, hazard ratio (HR) 1.032, 95 % CI 1.002–1.062), and high SUVperit/SUVovary (p = 0.046, HR 1.755, 95 % CI 1.011–3.047) were independent risk factors of recurrence. Patient group categorized by SUVperit/SUVovary showed significant difference in PFS (Log-Rank test, p = 0.001).

Conclusions

In patients with advanced serous EOC, preoperative SUVperit/SUVovary measured by [18F]FDG PET/CT provides significant incremental performance for prediction of recurrence.

Key points

• PET/CT data from advanced serous epithelial ovarian cancer patients were analysed.

• Prognostic value of SUV ratio between metastatic and primary tumour was investigated.

• SUV perit /SUV ovary provides incremental performance for prediction of recurrence.

Keywords

PET scan Peritoneum Metastasis Prognosis Ovarian cancer 

Abbreviations

EOC

Epithelial ovarian cancer

FIGO

International Federation of Gynaecology and Obstetrics

18F[FDG]

18F-fluorodeoxyglucose

PET

Positron emission tomography

CT

Computed tomography

SUV

Standardized uptake value

LN

Lymph node

perit

Peritoneal metastatic lesion

dist

Distant extra-peritoneal metastatic lesion

HR

Hazard ratio

CI

Confidence interval

OS

Overall survival

Notes

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Gi Jeong Cheon.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Ethical approval

Institutional Review Board approval was obtained.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Study subjects or cohorts overlap

Data from 73 patients in a previous study were included in the current analysis [14]. This study is different from previous one in that it performed lesion-specific analysis.

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

References

  1. 1.
    Heintz AP, Odicino F, Maisonneuve P, et al. (2006) Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 Suppl 1:S161-192.Google Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMedGoogle Scholar
  3. 3.
    Angioli R, Capriglione S, Aloisi A et al (2014) Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol 35:7009–7015CrossRefPubMedGoogle Scholar
  4. 4.
    Harter P, Muallem ZM, Buhrmann C et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121:615–619CrossRefPubMedGoogle Scholar
  5. 5.
    Chang SJ, Bristow RE (2012) Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol 125:483–492CrossRefPubMedGoogle Scholar
  6. 6.
    Braicu EI, Fotopoulou C, Van Gorp T et al (2013) Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol 128:245–251CrossRefPubMedGoogle Scholar
  7. 7.
    Chi DS, Bristow RE, Armstrong DK, Karlan BY (2011) Is the easier way ever the better way? J Clin Oncol 29:4073–4075CrossRefPubMedGoogle Scholar
  8. 8.
    Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627CrossRefPubMedGoogle Scholar
  9. 9.
    Winter WE 3rd, Maxwell GL, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26:83–89CrossRefPubMedGoogle Scholar
  10. 10.
    Makar AP, Baekelandt M, Trope CG, Kristensen GB (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175–180CrossRefPubMedGoogle Scholar
  11. 11.
    Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78:21–27CrossRefPubMedGoogle Scholar
  12. 12.
    Bachmann C, Bachmann S, Fehm T et al (2012) Nodal status--its impact on prognosis in advanced ovarian cancer. J Cancer Res Clin Oncol 138:261–267CrossRefPubMedGoogle Scholar
  13. 13.
    Kobel M, Reuss A, du Bois A et al (2010) The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222:191–198CrossRefPubMedGoogle Scholar
  14. 14.
    Chung HH, Lee M, Kim HS, et al. (2017) Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer. Eur Radiol 27(11):4510–4515Google Scholar
  15. 15.
    Mutch DG, Prat J (2014) 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 133:401–404CrossRefPubMedGoogle Scholar
  16. 16.
    Lee JW, Cho A, Lee JH et al (2014) The role of metabolic tumor volume and total lesion glycolysis on (1)(8)F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 41:1898–1906CrossRefPubMedGoogle Scholar
  17. 17.
    Chung HH, Kwon HW, Kang KW et al (2012) Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19:1966–1972CrossRefPubMedGoogle Scholar
  18. 18.
    Pfister D, Porres D, Heidenreich A et al (2016) Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 43:1410–1417CrossRefPubMedGoogle Scholar
  19. 19.
    Vaidyanathan G, McDougald D, Choi J et al (2016) Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. J Nucl Med 57:967–973CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Einhorn N, Nilsson B, Sjovall K (1985) Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 55:2019–2025PubMedGoogle Scholar
  21. 21.
    Farias-Eisner R, Teng F, Oliveira M et al (1994) The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 55:108–110CrossRefPubMedGoogle Scholar
  22. 22.
    Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61:413–420PubMedGoogle Scholar
  23. 23.
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166CrossRefPubMedGoogle Scholar
  24. 24.
    Berek JS (2009) Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer 19(Suppl 2):S18–S20CrossRefPubMedGoogle Scholar
  25. 25.
    Hofman MS, Hicks RJ (2016) How We Read Oncologic FDG PET/CT. Cancer Imaging 16:35CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95CrossRefPubMedGoogle Scholar
  27. 27.
    Chi DS, Abu-Rustum NR, Sonoda Y et al (2004) The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol 94:307–311CrossRefPubMedGoogle Scholar
  28. 28.
    Cohen-Mouly S, Badia A, Bats AS et al (2009) Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int J Gynecol Cancer 19:1662–1665CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2017

Authors and Affiliations

  • Hyun Hoon Chung
    • 1
  • Jae-Weon Kim
    • 1
  • Noh-Hyun Park
    • 1
  • Yong Sang Song
    • 1
  • Gi Jeong Cheon
    • 2
  1. 1.Department of Obstetrics and Gynecology, Cancer Research InstituteSeoul National University College of MedicineSeoulRepublic of Korea
  2. 2.Department of Nuclear Medicine, Cancer Research InstituteSeoul National University College of MedicineSeoulRepublic of Korea

Personalised recommendations